
November 8, 2017 - By Peter Erickson
GlaxoSmithKline PLC (NYSE:GSK) is expected to pay $0.50 on Jan 11, 2018. The indicated annual dividend is $2.00. Shareholders owning the stock before Nov 9, 2017 will be eligible to receive the payout. Based on GlaxoSmithKline PLC’s current price of $35.82, the dividend is 1.39 %. This dividend’s record date is Nov 10, 2017 and the announcement date is Oct 25, 2017. The stock decreased 0.89% or $0.32 during the last trading session, reaching $35.82. About 805 shares traded. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since November 8, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.GlaxoSmithKline plc is a global healthcare company. The company has market cap of $86.71 billion. The Firm operates through three divisions: Pharmaceuticals, Vaccines and Consumer Healthcare. It has a 28.62 P/E ratio. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.Among 15 analysts covering GlaxoSmithKline (NYSE:GSK), 6 have Buy rating, 1 Sell and 8 Hold. Therefore 40% are positive. GlaxoSmithKline has $50 highest and $40 lowest target. $47.50’s average target is 32.61% above currents $35.82 stock price. GlaxoSmithKline had 23 analyst reports since September 8, 2015 according to SRatingsIntel. The rating was downgraded by Citigroup on Wednesday, July 5 to “Neutral”. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) earned “Buy” rating by Argus Research on Monday, December 7. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has “Underperform” rating given on Wednesday, September 14 by BNP Paribas. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) earned “Hold” rating by Bank of America on Thursday, October 26. Bank of America upgraded the shares of GSK in report on Wednesday, December 9 to “Buy” rating. The rating was initiated by Cantor Fitzgerald on Friday, February 26 with “Hold”. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) earned “Neutral” rating by Credit Suisse on Tuesday, October 20. On Tuesday, September 15 the stock rating was upgraded by BNP Paribas to “Neutral”. The firm earned “Neutral” rating on Tuesday, September 8 by Bank of America. On Friday, August 12 the stock rating was maintained by Argus Research with “Buy”.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



(adsbygoogle = window.adsbygoogle || []).push({});
TRADE IDEAS REVIEW – IS THIS THE BEST STOCK SCANNER?

Trade Ideas is arguably one of the top scanning tools available on the market right

Trade Ideas Pro helps traders find the best setups in the market right NOW

Scottrade and E*TRADE license Trade Ideas proprietary technology for their premium trading platforms. We have fully automated trading available through Lightspeed and Interactive Brokers.Trade Ideas is the BEST Tool for Scanning. I would be LOST without Trade ideas. Ross Cameron – Warrior Trading